Increasing diagnostic accuracy to grade dysplasia in Barrett’s esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1 by unknown
RESEARCH Open Access
Increasing diagnostic accuracy to grade
dysplasia in Barrett’s esophagus using an
immunohistochemical panel for CDX2,
p120ctn, c-Myc and Jagged1
Dipti M. Karamchandani1, Heather L. Lehman1, Sara E. Ohanessian1, Julie Massé1, Patricia A. Welsh1,
Robert D. Odze2, John R. Goldblum3, Arthur S. Berg4 and Douglas B. Stairs1*
Abstract
Background: Patients with non-dysplastic Barrett’s esophagus (ND-BE) and low-grade dysplasia (LGD) are typically
monitored by periodic endoscopic surveillance, while those with high-grade dysplasia (HGD) and esophageal
adenocarcinoma (EAC) are usually treated by more aggressive interventions like endoscopic mucosal resection,
ablation or surgery. Therefore, the accurate grading of dysplasia in Barrett’s esophagus (BE) is essential for proper
patient care. However, there is significant interobserver and intraobserver variability in the histologic grading of
BE dysplasia. The objective of this study was to create an immunohistochemical (IHC) panel that facilitates the
grading of BE dysplasia and can be used as an adjunct to histology in challenging cases.
Methods: 100 BE biopsies were re-graded for dysplasia independently by 3 subspecialized gastrointestinal pathologists.
IHC staining for CDX2, p120ctn, c-Myc and Jagged1 proteins was then performed and assessed by two separate
methods of semi-quantitative scoring. Scores were integrated using a principal component analysis (PCA) and
receiver operating characteristic (ROC) curve.
Results: Principal component analysis demonstrated the ability of this panel of proteins to segregate ND-BE/LGD
and HGD/EAC, as the expression of the four proteins is significantly altered between the two subsets. Analysis of
the receiver operating characteristic curve showed that this panel has the potential to aid in the grading of dysplasia in
these two subcategories with both high sensitivity and specificity. While not able to discriminate between ND-BE and
LGD, this panel of four proteins may be used as an adjunct to help discriminate subsets of ND-BE/LGD from HGD/EAC.
Conclusions: We propose that the maximum utility of this IHC panel of CDX2, p120ctn, c-Myc, and Jagged1 proteins
would be to distinguish between LGD and HGD in histologically challenging cases, given the aggressive interventions
still used for HGD in many institutions, and hence may aid in the optimal patient management. The results of this initial
study are promising, though further validation is needed before this panel can be used clinically, including future
randomized prospective studies with larger patient cohorts from diverse locations.
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Background
Esophageal adenocarcinoma (EAC) is the predominant
form of esophageal cancer in the United States [1] and inci-
dence of EAC has experienced the highest rate of increase
among all solid tumors during the past 30 years [2, 3]. EAC
is typically diagnosed at a late stage of the disease, and
therefore, has a poor 5-year survival rate of approximately
20 %. Barrett’s esophagus (BE) is a known precursor lesion
for EAC [4] and at present, the best predictive factor for
the future development of EAC is the identification of BE
with high-grade dysplasia (HGD).
The progression of BE through a metaplasia-dysplasia-
adenocarcinoma sequence is slow and unpredictable. The
rate of progression of patients with low-grade dysplasia
(LGD) historically was thought to be close to that of ND-
BE, under 1 %. However, more recent studies have sug-
gested a higher rate of progression for LGD (2–28 % per
year) [5–10]. Furthermore, HGD has a high rate of pro-
gression to EAC (6–60 % per year) [6, 10, 11]. Currently,
in many institutions, detection of non-dysplastic BE (ND-
BE) and BE with LGD necessitates periodic endoscopic
surveillance, whereas HGD and EAC warrants more ag-
gressive interventions like endoscopic resection, ablation
and/or esophagectomy [12, 13]. Therefore, accurate grad-
ing of dysplasia, and one could argue more so accurate
diagnosis of HGD/EAC, is crucial for optimal patient
management. However, grading BE dysplasia can be
challenging, and in fact, a recent multi-institution inter-
national study has documented that HGD in BE is over-
diagnosed in about 40 % of the cases, which can lead to
possible unwarranted therapy and mismanagement, in-
cluding unnecessary esophagectomy, in some patients
[14]. Currently, histologic assessment of BE biopsies re-
mains the gold standard for risk assessment [15]. Though,
histological examination does get complicated by signifi-
cant interobserver and intraobserver variability [5, 16, 17].
Thus, there is a need for adjunct markers that can be used
to assist histologic assessment in rendering a more accur-
ate diagnosis, especially in diagnostically challenging cases,
and probably more so for an accurate diagnosis of HGD/
EAC in BE, given the treatment implications.
In this study, we analyzed the expression of CDX2,
p120-catenin (p120ctn), c-Myc and Jagged1 proteins
and assessed the value of the combination of these four
proteins to aid in accurately grading dysplasia in BE bi-
opsy samples. We selected proteins that are involved in
independent signaling pathways and are differentially
regulated during the progression from ND-BE to EAC
[18, 19]. CDX2 is involved in initiation of transdifferen-
tiation of normal esophageal squamous epithelium into
columnar epithelium [20]. Its expression is high in ND-
BE and progressively decreases in dysplasia and EAC
[21]. p120ctn is a tumor suppressor gene. Prior studies
have shown that its expression is decreased in 20 % of
ND-BE and 70 % of EAC, compared to normal esopha-
geal squamous epithelium [22]. In contrast, c-Myc is an
oncogene that is upregulated in greater than 70 % of
EAC [6, 23]. Finally, Jagged1 is a Notch canonical path-
way member and is downregulated in various cancers,
including EAC [1, 2, 21, 24].
Discrimination between ND-BE, LGD, HGD and
EAC is important in determining appropriate patient
care. To this end, the purpose of this study was to de-
velop an ancillary immunohistochemical panel that can
be combined with histological analysis to facilitate the
discrimination of ND-BE, LGD, HGD, and EAC and
help to more accurately grade BE dysplasia, especially
in histologically challenging cases. In this initial study
we analyzed a cohort of 100 BE biopsy samples with
varying grades of dysplasia for differential expression of
these four proteins by IHC.
Methods
Cases
This research was approved by the Hershey Medical
Center Institutional Review Board. A Health Insurance
Portability and Accountability Act (HIPAA) compliant
retrospective review of surgical pathology files at the
Hershey Medical Center was performed. The pathology
database was searched for ND-BE, BE with LGD, HGD
and EAC cases (biopsies and endoscopic mucosal resec-
tions) diagnosed between 2001 and 2014 with available
formalin-fixed, paraffin embedded tissue blocks. Cases
diagnosed as BE with epithelial alterations indefinite for
dysplasia were excluded from this study. A total of 100
samples were retrieved and Hematoxylin and Eosin
(H&E)-stained slides were re-reviewed independently by
three subspecialized academic gastrointestinal (GI) pa-
thologists at three different institutions. All patients had
Barrett’s esophagus as defined by the American College
of Gastroenterology 3, which includes both histologic
(intestinal metaplasia with goblet cells) and endoscopic
(columnar-type mucosa) components [13]. The cases
were classified as ND-BE, BE with LGD, BE with HGD
and EAC (including intramucosal and submucosal EAC)
independently by these three GI pathologists using pre-
viously published diagnostic criteria [16, 25–27]. In brief,
the criteria were as follows:
Negative for dysplasia
The architecture is within normal limits. Although nu-
clear hyperchromasia, stratification and elongation can
be seen in the regenerative compartment, there is
complete surface maturation. The nuclei are arranged
in a uniform surface monolayer and do not vary greatly
in size or shape.
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LGD
Nuclear hyperchromasia, elongation and stratification is
seen in the basal compartment and these changes extend
to the surface epithelium. However, nuclear polarity is
maintained in LGD. Mild architectural complexity with
glandular crowding may be seen.
HGD
The biopsies showed severe cytologic atypia extending
to the surface epithelium, defined, among others, by
loss of nuclear polarity. Other cytologic features such
as marked nuclear enlargement, pleomorphism, hyper-
chromatism, and irregular nuclear membranes are also
present in HGD. Architectural features, such as glan-
dular complexity and distortion with crowding and di-
lated glands with intraluminal necrotic debris, are also
present.
Intramucosal EAC (IMC)
The diagnosis of IMC entails either single cell invasion of
lamina propria by neoplastic cells or abortive, angulated
glands infiltrating the lamina propria. The other criteria
include sheets of cells obliterating the lamina propria and
a never-ending/anastomosing gland pattern.
Submucosal EAC (SMC)
SMC requires unequivocal stromal desmoplasia to be
present in the biopsies.
Immunohistochemistry
IHC analysis was performed on 5 μm sections for CDX2,
p120ctn, c-Myc and Jagged1 proteins. Tissue sections
were baked 1 h at 55 °C, deparaffinized with xylene and
antigens were unmasked by heating in citrate buffer
(0.01 M, pH 6.0). Endogenous peroxidase activity was
blocked by incubation with 3 % peroxide for 6 min. The
slides were incubated overnight at 4 °C with primary
antibodies (CDX2: Biogenex, Fremont, CA, # Mu392A-
UC, dilution 1:50; p120ctn: BD Biosciences, San Jose,
CA, # 610134, dilution 1:100; c-Myc: Epitomics Inc.,
Burlingame, CA, # 1472-1, dilution 1:100). For antibody
detection, ImmPRESS (Vector Labs, Burlingame, CA)
anti-rabbit or anti-mouse antibodies were used. Slides
were incubated with DAB for 10 min and counterstained
with hematoxylin prior to coverslipping with Permount.
For Jagged1 and p53 staining, the Penn State Hershey
Molecular and Histopathology Core Research Lab per-
formed IHC on the GE Discovery XT stainer, using an
EDTA based retrieval solution (Ventana Medical Sys-
tems, Tucson, AZ). The slides were incubated with
Jagged1 antibody at a 1:400 dilution (Jagged1: Sigma
Aldrich, Saint Louis, MO, #HPA021555) and p53 was a
ready to use antibody from Ventana Medical Systems
(#790-2912).
IHC quantification
Immunohistochemical staining was evaluated on an
Olympus BX53 light microscope at 100×, 200× and
400× magnifications and images were captured using
an Olympus DP25 camera and Olympus CellSens Di-
mension software. All the immunohistochemical slides
were semi-quantitatively analyzed and interpreted without
knowledge of the histologic diagnosis by one person in
order to eliminate interobserver bias in interpretation of
the immunohistochemical results. These slides were ana-
lyzed at 200× using two different methods as follows:
Quartile scoring method
Score of 0 = no staining; 1 = 1 % to 25 % positive; 2 =
26 % to 50 % positive; 3 = 51 % to 75 % positive; 4 =
76 % to 100 % positive.
IRS scoring method
An immunoreactivity score (IRS) was utilized as previ-
ously described [24, 28]. IRS values are calculated as the
staining intensity value (0 to 3) multiplied by the esti-
mated value of the percentage of positively stained cells.
Percentage of stained cells was scored as: 1 = 10 % to
25 % positive; 2 = 26 % to 50 % positive; 3 = 51 % to
75 % positive; 4 = 76 % to 100 % positive. Intensity was
scored as: 0 = no staining; 1 = weak staining; 2 =moder-
ate staining; 3 = strong staining. If less than 10 % of the
cells were stained, a score of zero was given. Therefore,
the total IRS ranged from 0 to 12.
While the quartile scoring method is currently the
more standard method used by pathologists, the IRS
scoring method is a standard research tool and its util-
ity has been validated in multiple prior studies 24,28.
Therefore, both semi-quantitative methods were evalu-
ated to determine the best method in grading and diag-
nosing dysplasia in BE.
Statistical analysis
Samples were classified into two groups, ND-BE/LGD and
HGD/EAC based on histologic diagnosis and compared to
each other using the Student’s t-test. Analysis was also
performed to see if this panel could facilitate discrimin-
ation of ND-BE biopsies from LGD/HGD/EAC. Semi-
quantitative scoring and their subsequent analysis by
principal component analysis (PCA) and receiver operat-
ing characteristic (ROC) curve were performed. PCA was
applied to the four IHC staining scores to reduce the di-
mension to two principal components. The two principal
components were graphed and colored according to the
clinical status (ND-BE/LGD and HGD/EAC) of the pa-
tients. The first principal component versus clinical status
was separately graphed as a boxplot. To evaluate the util-
ity of the potential marker, a ROC curve was constructed
to assess the prediction ability to identify ND-BE/LGD
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and HGD/EAC patients using the scores of the immuno-
staining for the four proteins. All tests were carried out at
a significance level of 0.05. The statistical analysis was per-
formed using R version 3.0.0 (http://www.r-project.org).
Results
Patient characteristics
100 patient samples were included in the study. The ini-
tial diagnoses were ND-BE (n = 24), LGD (n = 23), HGD
(n = 24) and EAC (n = 29). The age of the patients
ranged from 31 to 89 years (mean 64.4, median 65) with
a male-to-female ratio of 4:1 (79 men and 21 women).
Histologic assessment of samples
Three subspecialized GI pathologists re-reviewed and
re-graded the 100-sample cohort independently using
criteria outlined above. Upon completion of histologic
assessment, the cohort was divided into:
1. Complete consensus: All three pathologists made
the same diagnosis independently in 62 of 100 samples
(62 %). This consisted of 26 ND-BE, 6 LGD, 9 HGD
and 21 EAC (Fig. 1a-d).
Only samples with a complete consensus diagnosis
were included in the initial statistical analyses (See
“Statistical analyses of scoring methods using complete
consensus cases” section below).
2. Partial consensus: Two of three pathologists were
in agreement and one was in disagreement in 37
samples (37/100 samples; 37 %). No individual
pathologist was in disagreement more than the
other pathologists, suggesting that these partial
consensus samples may represent diagnostically
challenging cases. These partial consensus cases
were as follows:
A. Partial consensus between BE-ND and LGD - 10/
37 cases.
B. Partial consensus between LGD and HGD - 7/37
cases.
C. Partial consensus between BE-ND and HGD - 1/37
cases. This case was diagnosed as ND-BE by two
pathologists and as HGD by the third.
D. Partial consensus between HGD and EAC - 19/37
cases.
3. Non-consensus: All three pathologists diagnosed one
sample differently. It was diagnosed as LGD by
the first, HGD by the second and EAC by the third
(1/100; 1 %).
Partial and non-consensus samples were examined
secondarily to see how they overlaid with consensus
samples (See “Statistical analyses of scoring methods
using partial/non-consensus cases” section below).
Fig. 1 Hematoxylin & Eosin staining. a Non-dysplastic Barrett’s mucosa characterized by uniform, bland nuclei arranged in a surface monolayer.
b Low-grade dysplasia exhibiting nuclear hyperchromasia, elongation and stratification extending up to the surface epithelium. c High-grade dysplasia
depicting increased architectural and cytologic complexity including loss of nuclear polarity. d Intramucosal adenocarcinoma characterized by severe
architectural distortion including angulated glands. (a-d, 100×)
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Immunohistochemical staining
CDX2
Expression of CDX2 decreased significantly through the
progression from ND-BE to EAC (Fig. 2). Nuclear CDX2
staining was present in the majority of glandular cells in
ND-BE and LGD samples, with an average score of 3.4
in ND-BE samples and 3.3 in LGD samples, using the
quartile scoring method (Fig. 2a and b). The percentage
of cells stained with CDX2 was decreased in HGD and
EAC samples, with an average score of 2.7 in both HGD
and EAC samples.
In HGD and EAC samples, nuclear CDX2 staining was
also decreased in intensity, with an average IRS score of 4.2
in HGD and 4.1 in EAC samples compared to an average
IRS score of 7.0 in ND-BE and 6.2 in LGD samples (Fig. 2c
and d). Average scores for CDX2 staining using the quartile
and IRS scoring methods are presented in Table 1.
ANOVA analysis of CDX2 scores revealed a significant de-
crease in expression of CDX2 expression as ND-BE pro-
gressed to EAC (p = 0.01 for quartile scoring, p ≤ 0.01 for
IRS scoring) (Additional file 1: Figure S1a and b).
p120ctn
p120ctn had a strong and well-defined expression pattern
at the membrane of the columnar epithelial cells of ND-
BE samples (Fig. 3a). For membranous p120ctn expres-
sion, ND-BE samples had an average score of 3.7 using
the quartile scoring method and an IRS score of 8.0. In
comparison, cytoplasmic p120ctn scores were on average
0.6 for the quartile scoring method and 0.6 for IRS scor-
ing. LGD samples showed expression of p120ctn at the
membrane as well as mislocalization to the cytoplasm of
some cells (Fig. 3b). p120ctn membranous expression was
scored as 4 with the quartile scoring method and the IRS
score was 10.0 in LGD samples. Cytoplasmic p120ctn
scores were lower, with an average quartile method score
of 0.7 and an IRS score of 0.8. p120ctn membranous ex-
pression was significantly decreased in HGD and EAC
samples and the protein was partially mislocalized to the
cytoplasm in a larger percentage of cells (Fig. 3c and d).
Membranous p120ctn staining scores were 3.6 for HGD
and 2.8 for EAC samples with the quartile scoring
method. IRS scores were significantly lower as well; 6.2 for
HGD and 4.1 for EAC. Conversely, cytoplasmic p120ctn
significantly increased in HGD and EAC samples com-
pared with ND-BE and LGD samples. Cytoplasmic
p120ctn staining scores were 2.1 for HGD and 3.0 for
EAC using the quartile scoring method. IRS scores were
2.4 for HGD and 3.0 for EAC. Average scores of the mem-
branous and cytoplasmic p120ctn staining are summa-
rized in Table 1. These data demonstrate that through the
progression from ND-BE to EAC, p120ctn membranous
expression is significantly decreased (p ≤ 0.001 for both
scoring methods) (Additional file 1: Figure S1c and d).
Conversely, p120ctn cytoplasmic expression is signifi-
cantly increased through disease progression (quartile
scoring method, p < 0.0001; IRS scoring, p ≤ 0.001)
(Additional file 1: Figure S1e and f ).
c-Myc
Immunohistochemical staining showed weak nuclear ex-
pression for c-Myc in ND-BE and LGD samples, with a
Fig. 2 CDX2 staining pattern in Barrett’s esophagus. a, b Non-dysplastic BE & Low-grade dysplasia, respectively, depicting diffuse nuclear staining.
c, d High-grade dysplasia & adenocarcinoma, respectively, depicting a decrease in nuclear intensity as well as percentage of positive cells.
(a&b, 200×; c&d, 400×)
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lower percentage of positively stained cells compared to
HGD and EAC. IHC scoring of ND-BE c-Myc staining
yielded an average scores of 2.2 with the quartile scoring
method and an average IRS score of 2.8 (Fig. 4a). LGD
samples had an average quartile score of 2.2 and an IRS
score of 3.2 (Fig. 4b). In contrast, HGD and EAC sam-
ples had significantly stronger nuclear c-Myc expression
(Fig. 4c and d). The quartile scoring method resulted in
average staining scores of 2.8 for HGD and 2.7 for EAC,
indicating an increased percentage of positive cells when
compared to ND-BE and LGD. However, IRS scoring re-
sulted in a significantly higher score of 5.2 for HGD
samples and 4.6 for EAC when compared to ND-BE and
LGD. Means of the c-Myc staining scores are summarized
in Table 1. These data suggest that nuclear c-Myc expres-
sion increases during the progression of the disease. Al-
though an increase in score was seen by both scoring
methods, the results were statistically significant only by
IRS scoring (quartile scoring method, p = 0.17; IRS scor-
ing, p = 0.02) (Additional file 1: Figure S1g and h).
Jagged1
Jagged1 had weak membranous staining of columnar
cells in ND-BE samples and a staining score of 3.6 using
the quartile scoring method. ND-BE samples yielded an
IRS score of 4.3 (Fig. 5a). The same localization was
Table 1 Mean values of IHC scores for CDX2, p120ctn, c-Myc and Jagged1
CDX2 Membranous p120ctn Cytoplasmic p120ctn c-Myc JAG-1
Quartile scoring method
ND-BE 3.4 3.7 0.6 2.2 3.6
LGD 3.3 4.0 0.7 2.2 3.5
HGD 2.7 3.6 2.1 2.8 3.8
EAC 2.7 2.8 3.0 2.7 3.9
p-value p ≤ 0.01 p ≤ 0.001 p < 0.0001 p = 0.17 p = 0.10
IRS scoring method
ND-BE 7.0 8.0 0.6 2.8 4.3
LGD 6.2 10.0 0.8 3.2 5.2
HGD 4.2 6.2 2.4 5.2 5.3
EAC 4.1 4.1 3.0 4.6 6.6
p-value p ≤ 0.01 p ≤ 0.001 p ≤ 0.001 p ≤ 0.05 p ≤ 0.001
Fig. 3 p120ctn staining pattern in Barrett’s esophagus. a Non-dysplastic BE depicting a strong and well-defined membranous expression pattern
in the columnar epithelial cells. b Low-grade dysplasia depicting a membranous expression as well as cytoplasmic mislocalization in some cells. c,
d High-grade dysplasia & adenocarcinoma, respectively, showing a significant decrease in membranous staining and partial cytoplasmic mislocalization
in neoplastic cells. (a&c, 400×; b&d, 200×)
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observed in LGD samples but with slightly diffuse cyto-
plasmic staining (Fig. 5b). Using the quartile scoring
method the score for LGD samples was 3.5 and the IRS
score was 5.2. In HGD and EAC samples, Jagged1 was
detected in a large proportion of cells and appeared to
be highly diffuse with moderate membranous and cyto-
plasmic expression (Fig. 5c and d). Using the quartile
scoring method the score for HGD was 3.8 and EAC
was 3.9. While the quartile scoring method did not show
a statistically significant change in Jagged1 staining (p =
0.10), IRS scoring of membranous Jagged1 expression
showed a significant increase in expression from ND-
BE/LGD (IRS score 4.8) to HGD/EAC (IRS score 6.0)
patient samples (p ≤ 0.001) (Additional file 1: Figure S1i
and j). Also, Jagged1 was significantly higher in HGD
compared with LGD when analyzed using IRS scoring,
Fig. 4 c-Myc staining pattern in Barrett’s esophagus. a, b Non-dysplastic BE & Low-grade dysplasia, respectively showing weak nuclear expression.
c, d High-grade dysplasia & adenocarcinoma, respectively, depicting a stronger nuclear expression. (a&b, 200×; c&d, 400×)
Fig. 5 Jagged1 staining pattern in Barrett’s esophagus. a Non-dysplastic Barrett’s mucosa showing faint membranous expression. b Low-grade
dysplasia showing membranous localization along with weak diffuse cytoplasmic staining. c, d High-grade dysplasia & adenocarcinoma, respectively,
showing diffuse staining with moderate membranous and cytoplasmic expression. The inset in panel (d) further highlights this staining pattern and
staining intensity. (a&d, 200×; b&c, and d-inset 400×)
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illustrating a potential switch of expression occurring be-
tween these two pathologic states. Means of the Jagged1
staining scores using two scoring methods are presented
in Table 1.
Statistical analyses of scoring methods using complete
consensus cases
Only samples with a complete consensus diagnosis were
included in initial statistical analyses (i.e. 62 of 100 sam-
ples analyzed). To determine the ability of these four
markers to classify varying grades of neoplasia in BE, we
utilized the scores obtained from the quantification of
each of the four proteins together using two individual
scoring methods described above. We rigorously ana-
lyzed the ability of the four-marker panel to distinguish
between ND-BE, LGD, HGD, or EAC in any manner.
Unsupervised PCA analysis of the two scoring methods
looked at whether the four proteins could aid in classi-
fying ND-BE from LGD/HGD/EAC. Our analysis dem-
onstrated that the markers were not able to separate
ND-BE samples from the combined LGD/HGD/EAC
samples as a group.(p ≥ 0.05; data not shown).
The greatest changes in expression of the four markers
were detected between LGD and HGD. For the quartile
scoring method, where a score of zero indicates no stain-
ing and scores 1 through 4 are divided into quartiles of
percentage of cells stained, an unsupervised PCA was able
to segregate samples into two groups – ND-BE/LGD and
HGD/EAC patients (Fig. 6a). This observation was con-
firmed by the box plot graph of the first principal compo-
nent, which showed a significant change in the
distribution of the samples over the two groups (p ≤ 0.001)
(Fig. 6b). A ROC curve was also plotted to determine the
ability of the integrated IHC scores for the four proteins
to distinguish ND-BE/LGD from HGD/EAC. ROC ana-
lysis provided 81 % sensitivity and 83 % specificity, with
area under the curve of 0.866 (Fig. 6c).
An unsupervised PCA on the IRS scoring method,
where a score incorporates both the percentage of cells
stained and intensity of the stain, was also able to segre-
gate samples into ND-BE/LGD and HGD/EAC groups
(Fig. 6d). The box plot graph of the first principal com-
ponent showed a significant change in the distribution
of the samples over the two groups (p ≤ 0.001) (Fig. 6e).
The ROC curve analysis provided 87 % sensitivity and
87 % specificity and area under the curve of 0.956
(Fig. 6f ).
Upon examining sensitivity, specificity, and area under
the curve, these data suggest that although both scoring
methods were able to separate the samples into two subcat-
egories, the IRS scoring method results in higher sensitivity
and specificity and a lower area under the curve. Therefore,
the IRS scoring method is the better and more accurate
method to segregate ND-BE/LGD and HGD/EAC patients.
Fig. 6 Statistical analysis of IHC quantification using complete consensus samples. a Principal component analysis of quartile scoring method
scores was generated from ND-BE (black circles), LGD (red circles), HGD (green circles) and EAC (blue circles) consensus samples. A demarcation
line was added for easy visualization. b Beeswarm plot representing the distribution of ND-BE/LGD and HGD/EAC consensus samples when scored
with the quartile scoring method. c Receiving operating characteristic curve depicting the accuracy of CDX2, p120ctn, c-Myc and Jagged1 expression
scores as markers of diagnosis with a confidence interval of 95 % for the quartile scoring method. The area under curve for this ROC was 0.866. d PCA
of IRS scores using IRS scoring, with circles representative of disease state as noted in (a). e Beeswarm plot when scored with the IRS scoring method
(p≤ 0.001). f ROC curve when scored with IRS scoring. The area under curve for this ROC was 0.956
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Statistical analyses of scoring methods using partial/
non-consensus cases
Although the quartile scoring method is currently the
more conventional method used by pathologists, this
scoring method was excluded for analysis of the partial/
non-consensus patient samples in this sentinel study
since it did not perform as well as the IRS scoring
method. PCA analysis of the quartile scoring method
demonstrated considerable overlap of ND-BE and HGD
samples as well as lower sensitivity, specificity, and ROC
area under the curve values. For these reasons, we fo-
cused on IRS scoring to test if our IHC panel can aid in
the accurate diagnosis of partial/non-consensus samples.
We applied the PCA analysis of the consensus samples
to the 38 partial/non-consensus samples to examine if
the parameters used to segregate complete consensus
samples would also be able to segregate partial/non-con-
sensus samples. This was completed for the IRS scoring
method, as ROC curve analysis and area under the curve
demonstrated that the IRS scoring method is the best
predictive scoring method for BE dysplasia classification.
These results are displayed as a graph of principal com-
ponent 1 versus principal component 2 (Fig. 7).
These hybrid PCAs demonstrate that a significant pro-
portion of the partial consensus samples also segregate
based on the majority diagnosis of the sample by two of
the three expert GI pathologists. For IRS scoring, seven
of nine partial consensus ND-BE samples were correctly
clustered into the consensus ND-BE/LGD group while
four of six partial consensus LGD samples clustered cor-
rectly. All partial consensus HGD and EAC samples
clustered with the consensus HGD/EAC cases. The one
non-consensus case (diagnosed as LGD by one GI path-
ologist, HGD by the second and EAC by the third) over-
laid with the complete consensus HGD/EAC cases.
Nonetheless, ROC curve analysis demonstrated 89 %
sensitivity and 90 % specificity and area under the curve
of 0.948 irrespective of the consensus status of the sam-
ples (data not shown). These data suggest that IRS
scoring, which takes into account both the percentage
of cells stained as well as the intensity of the stain, can
better predict the diagnosis of diagnostically challen-
ging cases.
Partial consensus cases may represent interobserver and
intraobserver variability, diagnostically challenging cases,
or a combination thereof. All partial consensus cases (37
samples; 1 non-consensus sample was excluded) were re-
evaluated based on pathology by the three subspecialized
GI pathologists. Specifically, the pathologist with the non-
consensus interpretation in each case re-read the respect-
ive slides having been supplied the interpretations of all
three pathologists. Reinterpretations of the partial conse-
nus samples demonstrated that the pathologists changed
their diagnoses in 21 of 37 (57 %) samples (data not
shown). Upon analysis of the changes in diagnosis, no new
discernable patterns or associations emerged in relation to
the diagnostic categories or individual pathologists. Given
that there was no significant shift in diagnoses after reinter-
pretation, we believe this indicates that these cases are in
fact diagnostically challenging, and further strengthens the
value and relevance of our proposed IHC panel for use in
diagnostically challenging cases of BE dysplasia.
Tp53 expression as a marker of LGD progression
As mentioned previously, two of the six partial consen-
sus LGD samples clustered with the consensus HGD/
EAC cases upon PCA analysis. Since the majority of the
partial consensus samples overlap closely with the con-
sensus samples, this allows us to further analyze any out-
liers. We questioned whether the partial consensus LGD
samples that clustered with HGD/EAC cases (which we
have termed “outliers”) (Fig. 7), would represent disease
that would be more likely to progress to HGD/EAC. To
test this we investigated the Tp53 status of the six partial
consensus LGD samples, as Tp53 is increasingly being
implemented as a marker of LGD progression [29, 30].
IHC analysis of Tp53 demonstrated that two of the six
partial consensus LGD samples had positive staining. Of
the two positive samples, one was an outlier that had
clustered with the HGD/EAC samples (Additional file 2:
Figure S2). These data demonstrate that there is no rela-
tionship between the LGD outlier samples and Tp53 sta-
tus, and therefore, Tp53 analysis does not complement
our proposed four-marker IHC panel.
Discussion
Barrett’s esophagus is the predominant risk factor for
EAC, the most prevalent form of esophageal cancer in
the United States. The accurate grading of dysplasia in
BE is subject to significant interobserver and intraobser-
ver variability, and this has been confirmed by multiple
Fig. 7 Statistical analysis of IHC quantification using partial/non-
consensus samples. Non-consensus samples overlaid onto the
PCA analysis of the consensus samples when scored with the IRS
scoring method. ND-BE (black triangles), LGD (red triangles), HGD
(green triangles) and EAC (blue triangles) are non-consensus samples
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prior studies [5, 16, 17]. Notably in this study, three sub-
specialized GI pathologists independently and blindly re-
graded dysplasia in 100 BE biopsies. Despite using the
same diagnostic criteria outlined above, the three GI pa-
thologists achieved partial or no consensus in a substantial
number of cases (38 %). Noticeably, no single pathologist
was in disagreement more than the other pathologists in
the partial consensus cases, proving that some of these in-
deed are diagnostically challenging cases. Accurate grad-
ing of dysplasia and especially discrimination of LGD
from HGD is important because of the aggressive treat-
ment interventions still used for HGD in many institu-
tions. A recent multicenter international study concluded
that HGD in BE is overdiagnosed in about 40 % of the
cases, which can lead to possible unwarranted therapy and
grave mismanagement, including unnecessary esophagec-
tomy, in some patients [14]. All these data reemphasize
the variability that exists when diagnosing dysplasia in BE,
even amongst specialized GI pathologists, and the need
for a diagnostic adjunct to help more accurately grade BE
dysplasia, especially in diagnostically challenging cases.
No reliable diagnostic markers are currently available to
aid in the diagnosis of BE, which is based on histopatho-
logic examination of biopsies. In this study, we analyzed
the expression of four proteins from different signaling
pathways (CDX2, p120ctn, c-Myc and Jagged1) in the pro-
gression of ND-BE to EAC, with the objective to increase
the diagnostic accuracy of grading neoplasia in BE. We
initially focused our analyses on the 62 samples that had
complete diagnostic consensus between three independ-
ent pathologists. Partial/non-consensus samples were ex-
amined secondarily. We found that in cases in which
there was a complete consensus, regardless of the scoring
method used, nuclear CDX2 and p120ctn expression were
both significantly decreased between ND-BE/LGD and
HGD/EAC samples, whereas c-Myc and Jagged1 expres-
sion were both upregulated in the HGD/EAC groups.
PCA analysis that integrates the score of each of these
four proteins illustrates that a combinatorial protein ex-
pression analysis approach can segregate the patients into
two broad categories (ND-BE/LGD and HGD/EAC) by
both quartile and IRS scoring methods.
When we applied the PCA analysis of the consensus
samples to the partial/non-consensus samples, the hy-
brid PCA demonstrated that a significant proportion of
the partial consensus samples also segregated based on
the majority diagnosis of the sample. Therefore, these
four proteins together in conjunction with histologic
analysis, are a promising panel that may more accurately
classify BE samples between ND-BE/LGD and HGD/
EAC with high sensitivity and specificity.
Some of these markers have been studied in dysplastic
processes in other organ systems as well. For example, up-
regulation of p120ctn was seen in 37 % of gastric dysplasia
cases and 66 % of gastric carcinoma cases in one study,
sometimes associated with reduced membranous expres-
sion [31]. Also, c-myc copy number gain has been found
to play a key role in the process of disease progression in
cervical dysplasia [32, 33]. CDX2 staining has shown vary-
ing results in gastric neoplasia. CDX2 was not detected in
normal gastric mucosa, while some studies have shown
that CDX2 is associated with gastric epithelial dysplasia in
44–87 % of cases and CDX2 expression was also seen to
gradually decrease from gastric epithelial dysplasia to early
and advanced gastric cancers. However, these studies
didn’t find any relationship between CDX2 expression and
the degree of dysplasia [34, 35]. On the contrary, another
study has shown that CDX2 expression was progressively
reduced in gastric dysplasia as well as cancer [36]. How-
ever, most importantly none of these markers has been
validated to be used in routine clinical practice for diagno-
sis or grading of dysplasia in these other organ systems.
While our study incorporates the expertise of three sub-
specialized GI pathologists and uses a four-marker protein
panel to test both consensus and non-consensus patient
samples, we acknowledge that this is an initial study test-
ing the utility of these biomarkers. Further validation will
be needed before this protein panel can be used clinically,
including prospective larger randomized studies involving
larger patient cohorts from diverse locations with clinic-
ally relevant end points. Additionally, the IHC protocol
used in this study will need to be streamlined with the use
of clinically validated IHC reagents and conditions before
it could be applied in routine clinical practice. However,
we believe that the initial results in this study are very
promising and this panel has future potential to serve as a
useful adjunct for those challenging cases where the path-
ologist is struggling with the accurate diagnosis, which
may ultimately affect optimal patient management.
A strength of this study is that two different semi-
quantitative IHC scoring methods were evaluated in an at-
tempt to determine the most clinically useful and accurate
way of scoring the four-marker panel for BE. We found
that the quartile scoring method had less sensitivity and
specificity as well as a lower area under the curve, as com-
pared to the IRS scoring. While scoring staining intensity
may not currently be the most conventional way of IHC
scoring in routine clinical practice, it appears with this
panel of proteins, taking into account both the percentage
and intensity of positively stained cells could lead to a
more accurate diagnosis, particularly in those diagnostic-
ally challenging cases. Therefore, IRS scoring appears to
be the better choice for the use of this four-marker protein
panel and its use in grading BE dysplasia. Having said that,
the sensitivity and specificity and/or area under the ROC
curve of the quartile scoring method was still found to be
more than many prior studies reported in the literature
that have used different biomarkers [37–39].
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A limitation of this study is the lack of progression data
for ND-BE and LGD patients. While our sample set ro-
bustly segregates ND-BE and LGD from HGD and EAC,
there are several samples from each group that segregate
with the opposite group, although none of those are EAC.
EAC samples completely segregate to the left of the PCA
plot. It is intriguing to speculate that the biologic behavior
of these samples may not match that of its histology.
Would the three HGD samples that segregate with ND-
BE and LGD samples be less likely to progress than the
majority of HGD samples? Conversely, would the four
ND-BE (n = 3) and LGD (n = 1) samples clustering with
HGD and EAC be more likely to progress than most ND-
BE and LGD? Since HGD is typically ablated, progression
data would not be possible for those patients. This study,
unfortunately, was a de-identified sample-set without
patient outcomes and therefore these questions will
need to be addressed in further studies that contain
patient outcome.
Another limitation of this study is that this panel of
biomarkers could not segregate ND-BE from LGD, and
given that some institutions are choosing to actively
treat LGD (either by ablation or endoscopic mucosal
resection), this panel may not be a good diagnostic ad-
junct in challenging cases where the differential is
between ND-BE and LGD. Despite this panel of bio-
markers being unable to distinguish one major clinical
decision point (no dysplasia versus dysplasia), it is ef-
fective at another decision point – LGD vs HGD.
Given that some institutions are still treating LGD
(surveillance) differently than HGD (with ablation and/
or endoscopic resection), this may be the more crucial
clinical decision point and our biomarker panel has
utility in this decision.
Indefinite for dysplasia was deliberately excluded from
this study, particularly because this study aimed to cre-
ate and test a diagnostic panel that can be used as an ad-
junct to aid in more accurate grading of dysplasia in BE.
Therefore, we wanted to use cases which were either de-
finitively negative or positive for dysplasia. Further stud-
ies would be needed to evaluate this panel of markers in
the “indefinite” category.
While a few markers have been evaluated previously for
their potential as BE diagnostic markers, none have per-
formed as well as the IHC panel presented here. The area
under the curve generated by ROC analysis ranged be-
tween 0.607 and 0.852 in prior studies [37–39]. Using our
own combination of markers, the areas under the ROC
curve are 0.86 and 0.956 for the quartile scoring method
and IRS scoring method, respectively, indicating a more
accurate diagnosis of the disease than previous studies.
Recently, AMACR (α-methylacyl coenzyme A race-
mase), an enzyme involved in β-oxidation of branched-
chain fatty acids, has been shown to be a useful marker
for differentiating ND-BE, LGD and HGD from each
other, suggesting that AMACR might be a useful diag-
nostic discriminator [40, 41]. In a large series, AMACR
was negative in all ND-BE cases, while it was positive
in LGD cases (38 %), HGD cases (81 %) and EAC
(72 %) [40]. However, the low sensitivity (less than
70 %) is a pitfall and does not allow a clinical use of
AMACR [42]. Tp53 was also analyzed because of its as-
sociation with dysplasia, though its staining has high
false-positive and false-negative rates [43, 44]. However,
Tp53 was never used in BE diagnosis because of the
low specificity and sensitivity results observed in the
IHC staining [45, 46]. Noticeably, in our study, the
combinatorial approach using the above four bio-
markers could segregate the samples into ND-BE/LGD
versus HGD/EAC categories with both high sensitivity
and specificity, although we acknowledge that these
markers may not be helpful to differentiate ND-BE
from LGD or HGD from EAC.
Interestingly, few studies have examined using a panel
of markers for BE progression or staging of the disease.
Bird-Lieberman et al. identified a panel of seven bio-
markers analyzed in a population-based study that in-
creases the accuracy of the prediction compared with
any individual marker [47]. It would be interesting to
evaluate whether these previously reported markers
could increase the accuracy of the diagnosis when com-
bined with our own panel. Nonetheless, we have shown
that a combinatorial morphologic/IHC approach could
successfully stratify patients into ND-BE/LGD and
HGD/EAC categories and has the potential to optimize
patient care. To date, this biomarker panel offers the
greatest promise for grading Barrett’s esophagus based
on ROC scores. Although histologic assessment still re-
mains the gold standard for diagnosis of BE dysplasia,
we propose that these proteins may serve as a useful as-
sessment adjunct in the future, to be used in cases that
are histologically challenging and where disagreement
exists about the grade of BE dysplasia.
Conclusions
In this initial study, we have identified a panel of four
proteins, CDX2, p120ctn, c-Myc and Jagged1, that may
be useful as an adjunct method of grading BE dysplasia.
This panel of proteins is able to segregate ND-BE/LGD
and HGD/EAC, distinguishing between LGD and HGD
with high sensitivity and specificity. We propose that
this IHC panel may be useful in discerning histologically
challenging cases and may able to aid in the accurate
diagnosis and management of patients. These promising
results are preliminary findings, and therefore, further
validation is required before the panel can be applied in
routine clinical practice.
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Additional files
Additional file 1: Figure S1. Expression levels of four-marker protein
panel in Barrett’s esophagus disease progression. (A) CDX2 expression
with the quartile scoring method and (B) IRS scoring, decreased from
ND-BE to EAC. (C) Membranous p120ctn expression with the quartile
scoring method and (D) IRS scoring, decreased from ND-BE to EAC. (E)
Cytoplasmic p120ctn expression with the quartile scoring method and (F)
IRS scoring, increased from ND-BE to EAC. (G) c-Myc expression with the
quartile scoring method and (H) IRS scoring, increased from ND-BE to
EAC. (I) Jagged1 expression with the quartile scoring method and (J) IRS
scoring. (JPG 156 kb)
Additional file 2: Figure S2. Tp53 expression in partial consensus
low-grade dysplasia cases. (A) Partial consensus low-grade dysplasia
sample exhibiting positive staining for Tp53. (B) Partial consensus
low-grade dysplasia sample exhibiting negative Tp53 staining. (a&b, 400×).
(JPG 1 mb)
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